Respiratory

Color keeps GSK generic off the market

Color keeps GSK generic off the market

By

GlaxoSmithKline claims that Sandoz needs to change the packaging for its generic Advair.

GSK's Breo approved in Europe, COPD market may be underestimated

GSK's Breo approved in Europe, COPD market may be underestimated

By

Known as Breo Ellipta in the US, GlaxoSmithKline's Relvar Ellipta was approved by the EMA for asthma and COPD. The overall market is expected to continue to grow, but an NIH study indicates more patient conversations need to happen.

GSK adds competitor to COPD market

By

The FDA approved the Breo/Ellipta combo, but analysts are wary about its potential to go beyond the COPD indication in the US.

Email Newsletters